Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes
The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
The question of whether Ozempic can be safely used in patients with Crohn's disease requires careful consideration, as there is no official contraindication listed in the Summary of Product Characteristics (SmPC) specifically for inflammatory bowel disease
People who have taken glucagon-like peptide-1 (GLP-1) receptor agonist drugs and suffer from severe gastrointestinal issues (GI), severe vomiting, and vision loss have begun seeking financial compensation
US$ 28.96
US$ 24.29
US$ 26.15
US$ 20.28
US$ 25.82
US$ 25.77
US$ 24.02
US$ 23.20
US$ 23.15
US$ 26.12
